Homology Medicines, Inc.
Symbool: 0T6G.L
LSE
21.56
USDMarktprijs vandaag
-0.7390
Koers/Winst Verhouding
-0.0083
Koers/Winst Groei Verhouding
283.62M
MRK Kapitalisatie
- 0.00%
DIV Rendement
Homology Medicines, Inc. (0T6G-L) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 82.7 | 175 | 155.9 | ||||||||
balance-sheet.row.short-term-investments | 0 | 43.4 | 141 | 47.5 | ||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.other-current-assets | 0 | 1.3 | 6 | 36 | ||||||||
balance-sheet.row.total-current-assets | 0 | 83.9 | 181 | 191.9 | ||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0.7 | 21.6 | 17.9 | ||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 25.8 | 2 | ||||||||
balance-sheet.row.tax-assets | 0 | 221.6 | 0 | 0 | ||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.total-non-current-assets | 0 | 222.2 | 47.5 | 19.8 | ||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.total-assets | 0 | 306.1 | 228.5 | 211.7 | ||||||||
balance-sheet.row.account-payables | 0 | 3.2 | 1.1 | 2.4 | ||||||||
balance-sheet.row.short-term-debt | 0 | 1.3 | 1.6 | 0.2 | ||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.long-term-debt-total | 0 | 49.4 | 11.9 | 5 | ||||||||
Deferred Revenue Non Current | 0 | -104.4 | 0 | 1.2 | ||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||
balance-sheet.row.other-current-liab | 0 | 7 | 18.7 | 11.4 | ||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 221.6 | 27.9 | 24.8 | ||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.capital-lease-obligations | 0 | 6.8 | 27.9 | 23.7 | ||||||||
balance-sheet.row.total-liab | 0 | 233.1 | 50.5 | 42.1 | ||||||||
balance-sheet.row.preferred-stock | 0 | 111.4 | 111.4 | 111.4 | ||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.retained-earnings | 0 | -542.1 | -429.1 | -424.1 | ||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | -0.4 | 0 | ||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 503.6 | 496.1 | 482.3 | ||||||||
balance-sheet.row.total-stockholders-equity | 0 | 73 | 178 | 169.7 | ||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 306.1 | 228.5 | 211.7 | ||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.total-equity | 0 | 73 | 178 | 169.7 | ||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||
Total Investments | 0 | 43.4 | 166.9 | 49.4 | ||||||||
balance-sheet.row.total-debt | 0 | 1.3 | 29.5 | 23.9 | ||||||||
balance-sheet.row.net-debt | 0 | -37.9 | -4.5 | -84.4 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -113 | -5 | -95.8 | ||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0.6 | 2.6 | 9.5 | ||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -19.2 | -38.8 | ||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 13.1 | 17.2 | ||||||||
cash-flows.row.change-in-working-capital | 0 | -7.2 | 3.4 | -41.8 | ||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.account-payables | 0 | 2.1 | -1 | -2.5 | ||||||||
cash-flows.row.other-working-capital | 0 | -9.3 | 4.3 | -39.3 | ||||||||
cash-flows.row.other-non-cash-items | 0 | 23.4 | -108.4 | 39.8 | ||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -0.2 | -1.3 | -2.4 | ||||||||
cash-flows.row.acquisitions-net | 0 | 0.6 | 130 | 48.4 | ||||||||
cash-flows.row.purchases-of-investments | 0 | -73.2 | -157.5 | -97.4 | ||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 174.2 | 65.5 | 49 | ||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | -48.4 | ||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 101.3 | 36.7 | -50.8 | ||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.common-stock-issued | 0 | 0.2 | 0.6 | 52.2 | ||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 0.6 | 52.2 | ||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0.2 | 0.6 | 52.2 | ||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.net-change-in-cash | 0 | 5.3 | -74.4 | -109 | ||||||||
cash-flows.row.cash-at-end-of-period | 0 | 39.3 | 34 | 108.4 | ||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 34 | 108.4 | 217.4 | ||||||||
cash-flows.row.operating-cash-flow | 0 | -96.2 | -113.7 | -109.8 | ||||||||
cash-flows.row.capital-expenditure | 0 | -0.2 | -1.3 | -2.4 | ||||||||
cash-flows.row.free-cash-flow | 0 | -96.5 | -114.9 | -112.1 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1.2 | 3.2 | 34 | ||||||||
income-statement-row.row.cost-of-revenue | 0 | 0.6 | 2.6 | 9.5 | ||||||||
income-statement-row.row.gross-profit | 0 | 0.6 | 0.6 | 24.4 | ||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.operating-expenses | 0 | 92.7 | 133.9 | 120.4 | ||||||||
income-statement-row.row.cost-and-expenses | 0 | 93.3 | 136.5 | 129.9 | ||||||||
income-statement-row.row.interest-income | 0 | 5.6 | 3.2 | 0.2 | ||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 5 | 134.5 | 0.2 | ||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.total-operating-expenses | 0 | 5 | 134.5 | 0.2 | ||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 0.6 | 2.6 | 9.5 | ||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||
income-statement-row.row.operating-income | 0 | -92.1 | -133.3 | -95.9 | ||||||||
income-statement-row.row.income-before-tax | 0 | -87.1 | 1.2 | -95.8 | ||||||||
income-statement-row.row.income-tax-expense | 0 | 0.3 | 0.7 | 0.5 | ||||||||
income-statement-row.row.net-income | 0 | -113 | -5 | -95.8 |
Vaak gestelde vragen
Wat is Homology Medicines, Inc. (0T6G.L) totale activa?
Homology Medicines, Inc. (0T6G.L) totale activa is 306119000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 2.827.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is 8.364.
Wat is de totale omzet van de onderneming?
De totale opbrengst is 6.819.
Wat is Homology Medicines, Inc. (0T6G.L) nettowinst (netto-inkomen)?
De nettowinst is -112961000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 1318000.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 92680000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 0.000.